View ValuationLENZ Therapeutics 将来の成長Future 基準チェック /26LENZ Therapeutics利益と収益がそれぞれ年間57%と49.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-116.7% 56%なると予測されています。主要情報57.0%収益成長率56.04%EPS成長率Pharmaceuticals 収益成長14.4%収益成長率49.4%将来の株主資本利益率-116.66%アナリストカバレッジGood最終更新日12 May 2026今後の成長に関する最新情報Major Estimate Revision • May 18Consensus revenue estimates fall by 23%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$24.9m to US$19.0m. Forecast losses increased from -US$3.99 to -US$4.50 per share. Pharmaceuticals industry in the US expected to see average net income decline 12% next year. Consensus price target down from US$39.57 to US$32.00. Share price fell 27% to US$7.34 over the past week.分析記事 • May 14Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their ForecastsIt's been a mediocre week for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the stock dropping 17% to...Price Target Changed • May 12Price target decreased by 18% to US$33.71Down from US$41.14, the current price target is an average from 7 analysts. New target price is 326% above last closing price of US$7.91. Stock is down 73% over the past year. The company is forecast to post a net loss per share of US$4.47 next year compared to a net loss per share of US$2.85 last year.Major Estimate Revision • Apr 23Consensus revenue estimates fall by 12%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$28.3m to US$24.9m. Forecast losses increased from -US$3.75 to -US$3.99 per share. Pharmaceuticals industry in the US expected to see average net income decline 14% next year. Consensus price target down from US$41.14 to US$39.57. Share price fell 5.1% to US$9.15 over the past week.Breakeven Date Change • Mar 29No longer forecast to breakevenThe 7 analysts covering LENZ Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$43.2m in 2028. New consensus forecast suggests the company will make a loss of US$10.1m in 2028.分析記事 • Mar 27LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To KnowLENZ Therapeutics, Inc. ( NASDAQ:LENZ ) just released its latest yearly report and things are not looking great. It was...すべての更新を表示Recent updatesMajor Estimate Revision • May 18Consensus revenue estimates fall by 23%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$24.9m to US$19.0m. Forecast losses increased from -US$3.99 to -US$4.50 per share. Pharmaceuticals industry in the US expected to see average net income decline 12% next year. Consensus price target down from US$39.57 to US$32.00. Share price fell 27% to US$7.34 over the past week.分析記事 • May 16Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's EstimatesToday is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...分析記事 • May 14Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their ForecastsIt's been a mediocre week for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the stock dropping 17% to...Price Target Changed • May 12Price target decreased by 18% to US$33.71Down from US$41.14, the current price target is an average from 7 analysts. New target price is 326% above last closing price of US$7.91. Stock is down 73% over the past year. The company is forecast to post a net loss per share of US$4.47 next year compared to a net loss per share of US$2.85 last year.お知らせ • May 04LENZ Therapeutics, Inc. to Report Q1, 2026 Results on May 11, 2026LENZ Therapeutics, Inc. announced that they will report Q1, 2026 results on May 11, 2026お知らせ • Apr 30LENZ Therapeutics, Inc., Annual General Meeting, Jun 12, 2026LENZ Therapeutics, Inc., Annual General Meeting, Jun 12, 2026.分析記事 • Apr 30LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Trimmed Their Revenue Forecasts By 12%Today is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...Major Estimate Revision • Apr 23Consensus revenue estimates fall by 12%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$28.3m to US$24.9m. Forecast losses increased from -US$3.75 to -US$3.99 per share. Pharmaceuticals industry in the US expected to see average net income decline 14% next year. Consensus price target down from US$41.14 to US$39.57. Share price fell 5.1% to US$9.15 over the past week.お知らせ • Apr 21Lenz Therapeutics Submits Marketing Authorization Application for Vizz for Treatment of Presbyopia in United KingdomLENZ Therapeutics, Inc. had submitted a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. Since receiving U.S. Food and Drug Administration (FDA) approval in July 2025, LENZ has moved rapidly to expand global access to VIZZ, with submission of the MAA in the United Kingdom representing the sixth ex-U.S. regulatory submission for VIZZ. The MAA submission is supported by positive data from three randomized, double-masked, controlled Phase 3 studies (CLARITY trials) conducted in the United States, in which VIZZ achieved all primary and secondary endpoints, demonstrating the ability to improve near vision within 30 minutes and last up to 10 hours. VIZZ was well tolerated with no serious treatment-related adverse events observed in over 30,000 treatment days across all three CLARITY trials. VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. Aceclidine is the sole active ingredient in VIZZ and provides rapid and durable near vision improvement. VIZZ is preservative-free and provided in single-dose vials. VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision. VIZZ (aceclidine ophthalmic solution) 1.44% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults. Do not use VIZZ if allergic to any of the ingredients. To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use. Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes. If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart. Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear. Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced. The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.Recent Insider Transactions • Mar 31President recently bought US$251k worth of stockOn the 27th of March, Evert Schimmelpennink bought around 28k shares on-market at roughly US$8.95 per share. This transaction amounted to 57% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Evert's only on-market trade for the last 12 months.分析記事 • Mar 29Analysts Just Slashed Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) EPS NumbersToday is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...Breakeven Date Change • Mar 29No longer forecast to breakevenThe 7 analysts covering LENZ Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$43.2m in 2028. New consensus forecast suggests the company will make a loss of US$10.1m in 2028.Seeking Alpha • Mar 27LENZ Therapeutics: Q4 Results Highlight A Worrying Lack Of Market Demand (Rating Downgrade)Summary Lenz Therapeutics (LENZ) is downgraded to a sell due to disappointing VIZZ product uptake and weak market demand signals from Q4 2025 results. Q4 2025 revenue was $1.6M on 20,000 prescriptions, with high S,G&A costs ($39.6M) and a net loss of $35.9M. LENZ faces significant risks: high cash burn, shareholder dilution, adverse events, and limited competitive moat with only one product. Despite strong cash reserves, high short interest and lack of market traction suggest LENZ is a value trap with further downside risk. Read the full article on Seeking Alpha分析記事 • Mar 27LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To KnowLENZ Therapeutics, Inc. ( NASDAQ:LENZ ) just released its latest yearly report and things are not looking great. It was...Price Target Changed • Mar 25Price target decreased by 13% to US$44.43Down from US$51.29, the current price target is an average from 7 analysts. New target price is 390% above last closing price of US$9.07. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$3.62 next year compared to a net loss per share of US$2.85 last year.お知らせ • Mar 18LENZ Therapeutics, Inc. to Report Q4, 2025 Results on Mar 24, 2026LENZ Therapeutics, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 24, 2026お知らせ • Mar 10LENZ Therapeutics Submits Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of PresbyopiaLENZ Therapeutics, Inc. had submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review and approval of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. The submission of the MAA in Europe represents the fifth ex-U.S. regulatory submission for VIZZ. The MAA submission is supported by positive data from three randomized, double-masked, controlled Phase 3 studies (CLARITY trials) conducted in the United States, in which VIZZ achieved all primary and secondary endpoints, demonstrating the ability to improve near vision within 30 minutes and last up to 10 hours. VIZZ was well tolerated with no serious treatment-related adverse events observed in over 30,000 treatment days across all three CLARITY trials. VIZZ was approved by the U.S. Food and Drug Administration (FDA) in July 2025 and is commercially available in the United States. The EMA submission marks the fifth ex-US submission and represents a significant milestone in LENZ’s international expansion strategy to establish VIZZ as a global brand. Presbyopia affects an estimated 1.8 billion people globally, and Europe represents one of the largest markets for vision correction products. LENZ intends to pursue commercialization in Europe through strategic partnerships, complementing partnerships already in place for Greater China, the Republic of Korea and Southeast Asia, Canada, and the Middle East region, and expects to provide further updates as the regulatory review progresses. Presbyopia is the inevitable loss of near vision associated with aging, impacting the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity of the lens reduces the ability of the lens to focus incoming light from near objects onto the retina. Adults over 50 years of age lose, on average, 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses. VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. Aceclidine is the sole active ingredient in VIZZ and provides rapid and durable near vision improvement. VIZZ is preservative-free and provided in single-dose vials. VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision. VIZZ (aceclidine ophthalmic solution) 1.44% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults. Do not use VIZZ if allergic to any of the ingredients. To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use. Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes. If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart. Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear. Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced. The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.Breakeven Date Change • Dec 31Forecast to breakeven in 2028The 7 analysts covering LENZ Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$45.8m in 2028. Average annual earnings growth of 56% is required to achieve expected profit on schedule.分析記事 • Dec 13Here's Why We're Not At All Concerned With LENZ Therapeutics' (NASDAQ:LENZ) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent Insider Transactions Derivative • Nov 19Chief Commercial Officer notifies of intention to sell stockShawn Olsson intends to sell 40k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of November. If the sale is conducted around the recent share price of US$25.60, it would amount to US$1.0m. Since December 2024, Shawn's direct individual holding has increased from 3.33k shares to 4.73k. Company insiders have collectively bought US$304k more than they sold, via options and on-market transactions, in the last 12 months.Recent Insider Transactions • Nov 11Co-Founder & Director recently bought US$239k worth of stockOn the 7th of November, James McCollum bought around 11k shares on-market at roughly US$22.79 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.分析記事 • Nov 08Earnings Beat: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsLENZ Therapeutics, Inc. ( NASDAQ:LENZ ) just released its third-quarter report and things are looking bullish. Results...お知らせ • Oct 29LENZ Therapeutics, Inc. to Report Q3, 2025 Results on Nov 05, 2025LENZ Therapeutics, Inc. announced that they will report Q3, 2025 results on Nov 05, 2025お知らせ • Sep 30LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United StatesLENZ Therapeutics, Inc. announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample distribution by the sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through ePharmacy partner and is anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025. VIZZ is powered by aceclidine, differentiated by its mechanism of action as a predominantly pupil-selectiveiotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle, resulting in a pinhole effect and uniquely achieves a sub-2mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift. In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes and lasted up to 10 hours. This level of near vision can restore the ability to read a phone screen and other everyday fine print without the assistance of reading glasses. Presbyopia is the inevitable loss of near vision associated with aging. It impacts the daily lives of nearly all people over the age of 45. seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced. ADVERSE REACTIONS The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.Price Target Changed • Aug 01Price target increased by 7.8% to US$48.50Up from US$45.00, the current price target is an average from 8 analysts. New target price is 62% above last closing price of US$29.96. Stock is up 25% over the past year. The company is forecast to post a net loss per share of US$2.62 next year compared to a net loss per share of US$2.34 last year.お知らせ • Aug 01Lenz Therapeutics, Inc. Announces Us Fda Approval of Vizz for the Treatment of PresbyopiaLENZ Therapeutics, Inc. announced the US Food and Drug Administration ("FDA") approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. Samples are anticipated in the United States as early as October 2025, with commercial product to be broadly available by mid-Q4 2025. Direct-to-eye care professional sales and marketing activities to be initiated immediately. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle resulting in a pinhole effect and uniquely achieves a sub-2mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift.ceclidine, the sole active ingredient in VIZZ, is a new chemical entity in the United States and its FDA approval marks a global first in the treatment of presbyopia. The FDA approval of VIZZ was based upon results from three randomized, double-masked, controlled Phase 3 studies. CLARITY 1 and CLARITY 2 were designed to evaluate the safety and efficacy of VIZZ in 466 participants dosed once daily for 42 days. CLARITY 3 evaluated 217 participants for long term safety over a 6-month duration of once daily dosing. In both CLARity 1 and CLARITY 2, VIZZ achieved all primary and secondary near vision improvement endpoints, demonstrating the ability to improve near vision within 30 minutes and last up to 10 hours. Near vision improvement was reproducible and consistent across both CLARITY 1 and 2. ADVERSE REACTIONS The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.Major Estimate Revision • Jul 30Consensus revenue estimates increase by 13%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from US$8.50m to US$9.57m. Forecast losses expected to reduce from -US$2.74 to -US$2.54 per share. Pharmaceuticals industry in the US expected to see average net income growth of 3.6% next year. Consensus price target up from US$45.00 to US$46.25. Share price fell 6.9% to US$30.76 over the past week.お知らせ • Jul 29LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of PresbyopiaLENZ Therapeutics, Inc. announced that CORXEL Pharmaceuticals has submitted the New Drug Application (NDA) for LNZ100 to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China (PRC). LENZ licensed the Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022. The NDA submission was supported by positive data from the Phase 3 JX07001 clinical trial of LNZ100 in patients with presbyopia in China. In this Phase 3 safety and efficacy trial, LNZ100 (1.75% aceclidine HCl) achieved the primary endpoint and secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one-line or more in distance visual acuity. The submission of the NDA for LNZ100 results in the achievement of the first milestone under the License and Collaboration Agreement with CORXEL (the "License"). Under the terms of the License, LENZ is eligible to receive up to $95.0 million of regulatory and sales milestones, as well as tiered mid single-digit to low double-digit royalties on net sales in Greater China.お知らせ • Jun 30+ 5 more updatesLENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell 3000 Value IndexLENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell 3000 Value IndexNew Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$8.4m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).お知らせ • May 01LENZ Therapeutics, Inc. to Report Q1, 2025 Results on May 07, 2025LENZ Therapeutics, Inc. announced that they will report Q1, 2025 results on May 07, 2025お知らせ • Apr 29LENZ Therapeutics, Inc., Annual General Meeting, Jun 10, 2025LENZ Therapeutics, Inc., Annual General Meeting, Jun 10, 2025.お知らせ • Apr 06LENZ Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.LENZ Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market OfferingSeeking Alpha • Mar 27LENZ Therapeutics Stock Is Attractive Before PDUFASummary LENZ Therapeutics, Inc.'s LNZ100 eye drop shows promising results for presbyopia, with strong phase 3 data and potential FDA approval by August 2025. LNZ100 demonstrated superior efficacy compared to AbbVie's Vuity, with a broad patient range and rapid onset of treatment effect. Survey data indicates high interest among eye care professionals, with 82% likely to prescribe LNZ100 if approved, targeting a $3bn market. Despite competitive risks, LNZ100's potential market penetration and Lenz's strong financial position make it a cautiously attractive investment. Read the full article on Seeking Alphaお知らせ • Mar 11LENZ Therapeutics, Inc. to Report Q4, 2024 Results on Mar 19, 2025LENZ Therapeutics, Inc. announced that they will report Q4, 2024 results at 12:30 PM, US Eastern Standard Time on Mar 19, 2025分析記事 • Jan 01Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Nov 27LENZ Therapeutics: Time For A PauseSummary Today, we take a look Lenz Therapeutics, which may be on the verge of approval for a 'best of breed' solution for near vision loss. The company has a solid balance sheet, is putting a sales organization in place and the compound is very likely to be approved next August. That said, the stock has more than doubled in the past six months and trading levels now exceed most analyst firm price targets. More legs to this rally or are the shares overdue for a pause? An analysis around Lenz Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaNew Risk • Nov 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$36m net loss in 3 years). Share price has been volatile over the past 3 months (9.7% average weekly change).お知らせ • Oct 30LENZ Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024LENZ Therapeutics, Inc. announced that they will report Q3, 2024 results on Nov 06, 2024お知らせ • Oct 28Corxel Pharmaceuticals and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100Corxel Pharmaceuticals and LENZ Therapeutics announced positive topline data from the Phase 3 JX07001 clinical trial of LNZ100 in patients with presbyopia in China. CORXEL is a leading biotech company committed to bringing innovative science and medicines to underserved patients with serious and life-threatening diseases. LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia. In this China Phase 3 safety and efficacy trial, LNZ100 (1.75% aceclidine HCl) achieved the primary endpoint and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). More results showed (all p<0.0001): Rapid onset: 84% and 69% achieved two-lines and three-lines or greater improvement at 30 minutes respectively. 3 hours post treatment: 88% and 74% achieved two-lines and three-lines or greater improvement at 3 hours respectively,and maintained their optimal distance visual acuity (i.e., not losing 5 or more letters). Long duration: 61% and 30% achieved two-lines and three-lines or greater improvement at 10 hours respectively. LNZ100 was well-tolerated with no serious treatment-related adverse events observed in the trial. The study was a Phase 3, multicenter, randomized, double-blind, vehicle-controlled study, including a 4-week efficacy study followed by a 5-month extension safety study, designed to evaluate the efficacy and safety of LNZ100 (an aceclidine-based ophthalmic solution) in participants with presbyopia. The objectives were to assess the potential of LNZ100 to improve near vision among Chinese presbyopia patients and to evaluate the efficacy and safety profiles. ?The trial has enrolled 300 participants, with a broad enrollment criteria of between 45 and 75 years of age with a refractive range of -4.0D SE to +1.0D SE, including those who had undergone laser-assisted cornea refractive surgery/monofocal IOL implantation. Presbyopia is a physiological phenomenon associated with aging that results in a progressively worsening ability to see nearby objects clearly. It is caused by the gradual hardening of the lens. This results in a decline of the eye's adjustment function, and the inability to focus the image of nearby objects on the retina, leading to a decline in near vision. Studies have shown that the onset of presbyopia typically occurs around the age of 38, reaching a prevalence rate of nearly 100% at the age of 52 in China. It is estimated that more than 400 million people in China suffer from presbyopia. Currently, the treatment options for presbyopia are very limited. Wearing glasses requires frequent removal and insertion, causing many inconveniences in work and life. Surgery, as an irreversible invasive operation, has a very limited acceptance. There are no approved drugs for the treatment of presbyopia in China and the medical need for non-invasive, safe, efficient and reversible treatments for presbyopia remains unsolved. LNZ100 (aceclidine) eye drops are being developed by LENZ Therapeutics and CORXEL acquired the Greater China rights for the development and commercialization in April 2022. LNZ100 is formulated with aceclidine, a miotic, and designed to achieve optimal pupil diameter without impacting distance vision, a key limitation of other miotics. Miotics are compounds that cause pupil constriction, or miosis, creating a pinhole effect that enables better focus of incoming light from near objects onto the retina. Research has shown that a pupil diameter below two millimeters (2 mm) is optimal for presbyopia treatment and results in clinically meaningful improvement in near vision. Unlike other miotics such as pilocarpine and carbachol, aceclidine’s mechanism of action is pupil-selective, meaning it can activate the iris sphincter muscle and cause miosis of the pupil to a diameter below 2 mm without overstimulating the ciliary muscles that can cause a myopic shift and impair distance vision. As a result, aceclidine does not require any remaining accommodation to improve near vision, broadening its benefits to older presbyopes whose lens has lost this capacity. Therefore, the company expected that users may be able to benefit from treatment even as they age from mid-40s to well into their mid-70s and across a broad range of refractive errors, as demonstrated in clinical testing to date.Seeking Alpha • Aug 30LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some RisksSummary Graphite Bio reverse merged with Lenz Therapeutics to focus on presbyopia, a $3bn+ market impacting 1.8 billion people globally. LNZ100, a 1.75% Aceclidine eye drop solution, conducted two positive phase 3 clinical trials for presbyopia, showing promising results. LENZ has a market cap of $617mn, cash balance of $226mn, submitted an NDA in August, and has $500mn peak sales estimate. Read the full article on Seeking Alphaお知らせ • Aug 13LENZ Therapeutics, Inc. Announces Submission of New Drug Application to U.S. Food and Drug Administration for Lnz100 for the Treatment of PresbyopiaLENZ Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for LNZ100 (an aceclidine-based ophthalmic solution) for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The NDA submission is supported by positive data from the pivotal Phase 3 CLARITY study of LNZ100 for the treatment of presbyopia. In the Phase 3 CLARITY study LNZ100 achieved all primary and secondary near vision improvement endpoints with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one line or more in distance visual acuity, demonstrating LNZ100 was well tolerated with no serious treatment-related adverse events observed in the over 30,000 treatment days monitored in the CLARITY study. The FDA has a 60-day filing review period to determine whether the NDA submission is complete and acceptable for review.お知らせ • Aug 08LENZ Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024LENZ Therapeutics, Inc. announced that they will report Q2, 2024 results on Aug 14, 2024お知らせ • Jul 15LENZ Therapeutics, Inc. announced that it expects to receive $30 million in fundingLENZ Therapeutics, Inc announced it has entered into a stock purchase agreement with new investor, Ridgeback Capital Investments L.P. for gross proceeds $30,000,000 on July 15, 2024.Recent Insider Transactions • May 16Co-Founder & Director recently bought US$501k worth of stockOn the 13th of May, James McCollum bought around 31k shares on-market at roughly US$15.99 per share. This transaction amounted to 5.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.お知らせ • May 03LENZ Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024LENZ Therapeutics, Inc. announced that they will report Q1, 2024 results on May 08, 2024お知らせ • Apr 03LENZ Therapeutics, Inc. Announces Positive Topline Data from Phase 3 CLARITY Presbyopia TrialsLENZ Therapeutics, Inc. announced positive topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45. In Phase 3 safety and efficacy trials (CLARITY 1 and 2), lead product candidate LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one-line or more in distance visual acuity. LNZ101 showed similar results, including achieving primary and secondary endpoints in both CLARITY 1 and 2, but did not show superiority to LNZ100. Based on these results, LENZ selected LNZ100 as its lead product candidate, for which it plans to submit a New Drug Application (NDA) in mid-2024. The high responder rate, rapid onset and long duration across a broad range of presbyopes ranging from 45 to 75 years of age and having a refractive range from -4.0 to +1.0D SE are consistent with features that patients are expecting from an effective treatment option. Based on these highly encouraging data, LENZ will direct towards NDA submission in mid-2024 for LNZ100, and preparations for commercialization in second half of 2025 upon FDA approval, with the goal of moving closer to helping many of the 128 million people experiencing symptoms of presbyopia in the United States.Board Change • Mar 25No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. No independent directors (7 non-independent directors). Director Fred Guerard was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.業績と収益の成長予測NasdaqGS:LENZ - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028138-28-22-55512/31/202765-109-128-132712/31/202619-141-208-13173/31/202621-109-87-87N/A12/31/202519-82-70-69N/A9/30/202518-59-46-45N/A6/30/20255-52-48-47N/A3/31/2025N/A-48-52-52N/A12/31/2024N/A-50-60-59N/A9/30/2024N/A-61-72-71N/A6/30/2024N/A-69-74-74N/A3/31/2024N/A-74-72-72N/A12/31/2023N/A-70-60-60N/A9/30/2023N/A-56-47-47N/A12/31/202215-11-4-4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: LENZ今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: LENZ今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: LENZ今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: LENZの収益 ( 49.4% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: LENZの収益 ( 49.4% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: LENZ 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 07:13終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋LENZ Therapeutics, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Jason Matthew GerberryBofA Global ResearchYigal NochomovitzCitigroup IncMatthew CaufieldH.C. Wainwright & Co.6 その他のアナリストを表示
Major Estimate Revision • May 18Consensus revenue estimates fall by 23%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$24.9m to US$19.0m. Forecast losses increased from -US$3.99 to -US$4.50 per share. Pharmaceuticals industry in the US expected to see average net income decline 12% next year. Consensus price target down from US$39.57 to US$32.00. Share price fell 27% to US$7.34 over the past week.
分析記事 • May 14Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their ForecastsIt's been a mediocre week for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the stock dropping 17% to...
Price Target Changed • May 12Price target decreased by 18% to US$33.71Down from US$41.14, the current price target is an average from 7 analysts. New target price is 326% above last closing price of US$7.91. Stock is down 73% over the past year. The company is forecast to post a net loss per share of US$4.47 next year compared to a net loss per share of US$2.85 last year.
Major Estimate Revision • Apr 23Consensus revenue estimates fall by 12%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$28.3m to US$24.9m. Forecast losses increased from -US$3.75 to -US$3.99 per share. Pharmaceuticals industry in the US expected to see average net income decline 14% next year. Consensus price target down from US$41.14 to US$39.57. Share price fell 5.1% to US$9.15 over the past week.
Breakeven Date Change • Mar 29No longer forecast to breakevenThe 7 analysts covering LENZ Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$43.2m in 2028. New consensus forecast suggests the company will make a loss of US$10.1m in 2028.
分析記事 • Mar 27LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To KnowLENZ Therapeutics, Inc. ( NASDAQ:LENZ ) just released its latest yearly report and things are not looking great. It was...
Major Estimate Revision • May 18Consensus revenue estimates fall by 23%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$24.9m to US$19.0m. Forecast losses increased from -US$3.99 to -US$4.50 per share. Pharmaceuticals industry in the US expected to see average net income decline 12% next year. Consensus price target down from US$39.57 to US$32.00. Share price fell 27% to US$7.34 over the past week.
分析記事 • May 16Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's EstimatesToday is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...
分析記事 • May 14Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their ForecastsIt's been a mediocre week for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the stock dropping 17% to...
Price Target Changed • May 12Price target decreased by 18% to US$33.71Down from US$41.14, the current price target is an average from 7 analysts. New target price is 326% above last closing price of US$7.91. Stock is down 73% over the past year. The company is forecast to post a net loss per share of US$4.47 next year compared to a net loss per share of US$2.85 last year.
お知らせ • May 04LENZ Therapeutics, Inc. to Report Q1, 2026 Results on May 11, 2026LENZ Therapeutics, Inc. announced that they will report Q1, 2026 results on May 11, 2026
お知らせ • Apr 30LENZ Therapeutics, Inc., Annual General Meeting, Jun 12, 2026LENZ Therapeutics, Inc., Annual General Meeting, Jun 12, 2026.
分析記事 • Apr 30LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Trimmed Their Revenue Forecasts By 12%Today is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...
Major Estimate Revision • Apr 23Consensus revenue estimates fall by 12%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$28.3m to US$24.9m. Forecast losses increased from -US$3.75 to -US$3.99 per share. Pharmaceuticals industry in the US expected to see average net income decline 14% next year. Consensus price target down from US$41.14 to US$39.57. Share price fell 5.1% to US$9.15 over the past week.
お知らせ • Apr 21Lenz Therapeutics Submits Marketing Authorization Application for Vizz for Treatment of Presbyopia in United KingdomLENZ Therapeutics, Inc. had submitted a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. Since receiving U.S. Food and Drug Administration (FDA) approval in July 2025, LENZ has moved rapidly to expand global access to VIZZ, with submission of the MAA in the United Kingdom representing the sixth ex-U.S. regulatory submission for VIZZ. The MAA submission is supported by positive data from three randomized, double-masked, controlled Phase 3 studies (CLARITY trials) conducted in the United States, in which VIZZ achieved all primary and secondary endpoints, demonstrating the ability to improve near vision within 30 minutes and last up to 10 hours. VIZZ was well tolerated with no serious treatment-related adverse events observed in over 30,000 treatment days across all three CLARITY trials. VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. Aceclidine is the sole active ingredient in VIZZ and provides rapid and durable near vision improvement. VIZZ is preservative-free and provided in single-dose vials. VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision. VIZZ (aceclidine ophthalmic solution) 1.44% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults. Do not use VIZZ if allergic to any of the ingredients. To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use. Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes. If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart. Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear. Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced. The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.
Recent Insider Transactions • Mar 31President recently bought US$251k worth of stockOn the 27th of March, Evert Schimmelpennink bought around 28k shares on-market at roughly US$8.95 per share. This transaction amounted to 57% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Evert's only on-market trade for the last 12 months.
分析記事 • Mar 29Analysts Just Slashed Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) EPS NumbersToday is shaping up negative for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders, with the analysts delivering a...
Breakeven Date Change • Mar 29No longer forecast to breakevenThe 7 analysts covering LENZ Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$43.2m in 2028. New consensus forecast suggests the company will make a loss of US$10.1m in 2028.
Seeking Alpha • Mar 27LENZ Therapeutics: Q4 Results Highlight A Worrying Lack Of Market Demand (Rating Downgrade)Summary Lenz Therapeutics (LENZ) is downgraded to a sell due to disappointing VIZZ product uptake and weak market demand signals from Q4 2025 results. Q4 2025 revenue was $1.6M on 20,000 prescriptions, with high S,G&A costs ($39.6M) and a net loss of $35.9M. LENZ faces significant risks: high cash burn, shareholder dilution, adverse events, and limited competitive moat with only one product. Despite strong cash reserves, high short interest and lack of market traction suggest LENZ is a value trap with further downside risk. Read the full article on Seeking Alpha
分析記事 • Mar 27LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To KnowLENZ Therapeutics, Inc. ( NASDAQ:LENZ ) just released its latest yearly report and things are not looking great. It was...
Price Target Changed • Mar 25Price target decreased by 13% to US$44.43Down from US$51.29, the current price target is an average from 7 analysts. New target price is 390% above last closing price of US$9.07. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$3.62 next year compared to a net loss per share of US$2.85 last year.
お知らせ • Mar 18LENZ Therapeutics, Inc. to Report Q4, 2025 Results on Mar 24, 2026LENZ Therapeutics, Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 24, 2026
お知らせ • Mar 10LENZ Therapeutics Submits Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of PresbyopiaLENZ Therapeutics, Inc. had submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review and approval of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. The submission of the MAA in Europe represents the fifth ex-U.S. regulatory submission for VIZZ. The MAA submission is supported by positive data from three randomized, double-masked, controlled Phase 3 studies (CLARITY trials) conducted in the United States, in which VIZZ achieved all primary and secondary endpoints, demonstrating the ability to improve near vision within 30 minutes and last up to 10 hours. VIZZ was well tolerated with no serious treatment-related adverse events observed in over 30,000 treatment days across all three CLARITY trials. VIZZ was approved by the U.S. Food and Drug Administration (FDA) in July 2025 and is commercially available in the United States. The EMA submission marks the fifth ex-US submission and represents a significant milestone in LENZ’s international expansion strategy to establish VIZZ as a global brand. Presbyopia affects an estimated 1.8 billion people globally, and Europe represents one of the largest markets for vision correction products. LENZ intends to pursue commercialization in Europe through strategic partnerships, complementing partnerships already in place for Greater China, the Republic of Korea and Southeast Asia, Canada, and the Middle East region, and expects to provide further updates as the regulatory review progresses. Presbyopia is the inevitable loss of near vision associated with aging, impacting the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity of the lens reduces the ability of the lens to focus incoming light from near objects onto the retina. Adults over 50 years of age lose, on average, 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses. VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. Aceclidine is the sole active ingredient in VIZZ and provides rapid and durable near vision improvement. VIZZ is preservative-free and provided in single-dose vials. VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision. VIZZ (aceclidine ophthalmic solution) 1.44% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults. Do not use VIZZ if allergic to any of the ingredients. To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use. Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes. If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart. Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear. Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced. The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.
Breakeven Date Change • Dec 31Forecast to breakeven in 2028The 7 analysts covering LENZ Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$45.8m in 2028. Average annual earnings growth of 56% is required to achieve expected profit on schedule.
分析記事 • Dec 13Here's Why We're Not At All Concerned With LENZ Therapeutics' (NASDAQ:LENZ) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Recent Insider Transactions Derivative • Nov 19Chief Commercial Officer notifies of intention to sell stockShawn Olsson intends to sell 40k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of November. If the sale is conducted around the recent share price of US$25.60, it would amount to US$1.0m. Since December 2024, Shawn's direct individual holding has increased from 3.33k shares to 4.73k. Company insiders have collectively bought US$304k more than they sold, via options and on-market transactions, in the last 12 months.
Recent Insider Transactions • Nov 11Co-Founder & Director recently bought US$239k worth of stockOn the 7th of November, James McCollum bought around 11k shares on-market at roughly US$22.79 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.
分析記事 • Nov 08Earnings Beat: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsLENZ Therapeutics, Inc. ( NASDAQ:LENZ ) just released its third-quarter report and things are looking bullish. Results...
お知らせ • Oct 29LENZ Therapeutics, Inc. to Report Q3, 2025 Results on Nov 05, 2025LENZ Therapeutics, Inc. announced that they will report Q3, 2025 results on Nov 05, 2025
お知らせ • Sep 30LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United StatesLENZ Therapeutics, Inc. announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample distribution by the sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through ePharmacy partner and is anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025. VIZZ is powered by aceclidine, differentiated by its mechanism of action as a predominantly pupil-selectiveiotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle, resulting in a pinhole effect and uniquely achieves a sub-2mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift. In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes and lasted up to 10 hours. This level of near vision can restore the ability to read a phone screen and other everyday fine print without the assistance of reading glasses. Presbyopia is the inevitable loss of near vision associated with aging. It impacts the daily lives of nearly all people over the age of 45. seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced. ADVERSE REACTIONS The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.
Price Target Changed • Aug 01Price target increased by 7.8% to US$48.50Up from US$45.00, the current price target is an average from 8 analysts. New target price is 62% above last closing price of US$29.96. Stock is up 25% over the past year. The company is forecast to post a net loss per share of US$2.62 next year compared to a net loss per share of US$2.34 last year.
お知らせ • Aug 01Lenz Therapeutics, Inc. Announces Us Fda Approval of Vizz for the Treatment of PresbyopiaLENZ Therapeutics, Inc. announced the US Food and Drug Administration ("FDA") approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. Samples are anticipated in the United States as early as October 2025, with commercial product to be broadly available by mid-Q4 2025. Direct-to-eye care professional sales and marketing activities to be initiated immediately. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle resulting in a pinhole effect and uniquely achieves a sub-2mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift.ceclidine, the sole active ingredient in VIZZ, is a new chemical entity in the United States and its FDA approval marks a global first in the treatment of presbyopia. The FDA approval of VIZZ was based upon results from three randomized, double-masked, controlled Phase 3 studies. CLARITY 1 and CLARITY 2 were designed to evaluate the safety and efficacy of VIZZ in 466 participants dosed once daily for 42 days. CLARITY 3 evaluated 217 participants for long term safety over a 6-month duration of once daily dosing. In both CLARity 1 and CLARITY 2, VIZZ achieved all primary and secondary near vision improvement endpoints, demonstrating the ability to improve near vision within 30 minutes and last up to 10 hours. Near vision improvement was reproducible and consistent across both CLARITY 1 and 2. ADVERSE REACTIONS The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.
Major Estimate Revision • Jul 30Consensus revenue estimates increase by 13%The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from US$8.50m to US$9.57m. Forecast losses expected to reduce from -US$2.74 to -US$2.54 per share. Pharmaceuticals industry in the US expected to see average net income growth of 3.6% next year. Consensus price target up from US$45.00 to US$46.25. Share price fell 6.9% to US$30.76 over the past week.
お知らせ • Jul 29LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of PresbyopiaLENZ Therapeutics, Inc. announced that CORXEL Pharmaceuticals has submitted the New Drug Application (NDA) for LNZ100 to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China (PRC). LENZ licensed the Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022. The NDA submission was supported by positive data from the Phase 3 JX07001 clinical trial of LNZ100 in patients with presbyopia in China. In this Phase 3 safety and efficacy trial, LNZ100 (1.75% aceclidine HCl) achieved the primary endpoint and secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one-line or more in distance visual acuity. The submission of the NDA for LNZ100 results in the achievement of the first milestone under the License and Collaboration Agreement with CORXEL (the "License"). Under the terms of the License, LENZ is eligible to receive up to $95.0 million of regulatory and sales milestones, as well as tiered mid single-digit to low double-digit royalties on net sales in Greater China.
お知らせ • Jun 30+ 5 more updatesLENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell 3000 Value IndexLENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell 3000 Value Index
New Risk • Jun 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$8.4m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).
お知らせ • May 01LENZ Therapeutics, Inc. to Report Q1, 2025 Results on May 07, 2025LENZ Therapeutics, Inc. announced that they will report Q1, 2025 results on May 07, 2025
お知らせ • Apr 29LENZ Therapeutics, Inc., Annual General Meeting, Jun 10, 2025LENZ Therapeutics, Inc., Annual General Meeting, Jun 10, 2025.
お知らせ • Apr 06LENZ Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.LENZ Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
Seeking Alpha • Mar 27LENZ Therapeutics Stock Is Attractive Before PDUFASummary LENZ Therapeutics, Inc.'s LNZ100 eye drop shows promising results for presbyopia, with strong phase 3 data and potential FDA approval by August 2025. LNZ100 demonstrated superior efficacy compared to AbbVie's Vuity, with a broad patient range and rapid onset of treatment effect. Survey data indicates high interest among eye care professionals, with 82% likely to prescribe LNZ100 if approved, targeting a $3bn market. Despite competitive risks, LNZ100's potential market penetration and Lenz's strong financial position make it a cautiously attractive investment. Read the full article on Seeking Alpha
お知らせ • Mar 11LENZ Therapeutics, Inc. to Report Q4, 2024 Results on Mar 19, 2025LENZ Therapeutics, Inc. announced that they will report Q4, 2024 results at 12:30 PM, US Eastern Standard Time on Mar 19, 2025
分析記事 • Jan 01Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Nov 27LENZ Therapeutics: Time For A PauseSummary Today, we take a look Lenz Therapeutics, which may be on the verge of approval for a 'best of breed' solution for near vision loss. The company has a solid balance sheet, is putting a sales organization in place and the compound is very likely to be approved next August. That said, the stock has more than doubled in the past six months and trading levels now exceed most analyst firm price targets. More legs to this rally or are the shares overdue for a pause? An analysis around Lenz Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
New Risk • Nov 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$36m net loss in 3 years). Share price has been volatile over the past 3 months (9.7% average weekly change).
お知らせ • Oct 30LENZ Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024LENZ Therapeutics, Inc. announced that they will report Q3, 2024 results on Nov 06, 2024
お知らせ • Oct 28Corxel Pharmaceuticals and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100Corxel Pharmaceuticals and LENZ Therapeutics announced positive topline data from the Phase 3 JX07001 clinical trial of LNZ100 in patients with presbyopia in China. CORXEL is a leading biotech company committed to bringing innovative science and medicines to underserved patients with serious and life-threatening diseases. LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia. In this China Phase 3 safety and efficacy trial, LNZ100 (1.75% aceclidine HCl) achieved the primary endpoint and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). More results showed (all p<0.0001): Rapid onset: 84% and 69% achieved two-lines and three-lines or greater improvement at 30 minutes respectively. 3 hours post treatment: 88% and 74% achieved two-lines and three-lines or greater improvement at 3 hours respectively,and maintained their optimal distance visual acuity (i.e., not losing 5 or more letters). Long duration: 61% and 30% achieved two-lines and three-lines or greater improvement at 10 hours respectively. LNZ100 was well-tolerated with no serious treatment-related adverse events observed in the trial. The study was a Phase 3, multicenter, randomized, double-blind, vehicle-controlled study, including a 4-week efficacy study followed by a 5-month extension safety study, designed to evaluate the efficacy and safety of LNZ100 (an aceclidine-based ophthalmic solution) in participants with presbyopia. The objectives were to assess the potential of LNZ100 to improve near vision among Chinese presbyopia patients and to evaluate the efficacy and safety profiles. ?The trial has enrolled 300 participants, with a broad enrollment criteria of between 45 and 75 years of age with a refractive range of -4.0D SE to +1.0D SE, including those who had undergone laser-assisted cornea refractive surgery/monofocal IOL implantation. Presbyopia is a physiological phenomenon associated with aging that results in a progressively worsening ability to see nearby objects clearly. It is caused by the gradual hardening of the lens. This results in a decline of the eye's adjustment function, and the inability to focus the image of nearby objects on the retina, leading to a decline in near vision. Studies have shown that the onset of presbyopia typically occurs around the age of 38, reaching a prevalence rate of nearly 100% at the age of 52 in China. It is estimated that more than 400 million people in China suffer from presbyopia. Currently, the treatment options for presbyopia are very limited. Wearing glasses requires frequent removal and insertion, causing many inconveniences in work and life. Surgery, as an irreversible invasive operation, has a very limited acceptance. There are no approved drugs for the treatment of presbyopia in China and the medical need for non-invasive, safe, efficient and reversible treatments for presbyopia remains unsolved. LNZ100 (aceclidine) eye drops are being developed by LENZ Therapeutics and CORXEL acquired the Greater China rights for the development and commercialization in April 2022. LNZ100 is formulated with aceclidine, a miotic, and designed to achieve optimal pupil diameter without impacting distance vision, a key limitation of other miotics. Miotics are compounds that cause pupil constriction, or miosis, creating a pinhole effect that enables better focus of incoming light from near objects onto the retina. Research has shown that a pupil diameter below two millimeters (2 mm) is optimal for presbyopia treatment and results in clinically meaningful improvement in near vision. Unlike other miotics such as pilocarpine and carbachol, aceclidine’s mechanism of action is pupil-selective, meaning it can activate the iris sphincter muscle and cause miosis of the pupil to a diameter below 2 mm without overstimulating the ciliary muscles that can cause a myopic shift and impair distance vision. As a result, aceclidine does not require any remaining accommodation to improve near vision, broadening its benefits to older presbyopes whose lens has lost this capacity. Therefore, the company expected that users may be able to benefit from treatment even as they age from mid-40s to well into their mid-70s and across a broad range of refractive errors, as demonstrated in clinical testing to date.
Seeking Alpha • Aug 30LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some RisksSummary Graphite Bio reverse merged with Lenz Therapeutics to focus on presbyopia, a $3bn+ market impacting 1.8 billion people globally. LNZ100, a 1.75% Aceclidine eye drop solution, conducted two positive phase 3 clinical trials for presbyopia, showing promising results. LENZ has a market cap of $617mn, cash balance of $226mn, submitted an NDA in August, and has $500mn peak sales estimate. Read the full article on Seeking Alpha
お知らせ • Aug 13LENZ Therapeutics, Inc. Announces Submission of New Drug Application to U.S. Food and Drug Administration for Lnz100 for the Treatment of PresbyopiaLENZ Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for LNZ100 (an aceclidine-based ophthalmic solution) for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The NDA submission is supported by positive data from the pivotal Phase 3 CLARITY study of LNZ100 for the treatment of presbyopia. In the Phase 3 CLARITY study LNZ100 achieved all primary and secondary near vision improvement endpoints with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one line or more in distance visual acuity, demonstrating LNZ100 was well tolerated with no serious treatment-related adverse events observed in the over 30,000 treatment days monitored in the CLARITY study. The FDA has a 60-day filing review period to determine whether the NDA submission is complete and acceptable for review.
お知らせ • Aug 08LENZ Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024LENZ Therapeutics, Inc. announced that they will report Q2, 2024 results on Aug 14, 2024
お知らせ • Jul 15LENZ Therapeutics, Inc. announced that it expects to receive $30 million in fundingLENZ Therapeutics, Inc announced it has entered into a stock purchase agreement with new investor, Ridgeback Capital Investments L.P. for gross proceeds $30,000,000 on July 15, 2024.
Recent Insider Transactions • May 16Co-Founder & Director recently bought US$501k worth of stockOn the 13th of May, James McCollum bought around 31k shares on-market at roughly US$15.99 per share. This transaction amounted to 5.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was James' only on-market trade for the last 12 months.
お知らせ • May 03LENZ Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024LENZ Therapeutics, Inc. announced that they will report Q1, 2024 results on May 08, 2024
お知らせ • Apr 03LENZ Therapeutics, Inc. Announces Positive Topline Data from Phase 3 CLARITY Presbyopia TrialsLENZ Therapeutics, Inc. announced positive topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45. In Phase 3 safety and efficacy trials (CLARITY 1 and 2), lead product candidate LNZ100 (1.75% aceclidine) achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, without losing one-line or more in distance visual acuity. LNZ101 showed similar results, including achieving primary and secondary endpoints in both CLARITY 1 and 2, but did not show superiority to LNZ100. Based on these results, LENZ selected LNZ100 as its lead product candidate, for which it plans to submit a New Drug Application (NDA) in mid-2024. The high responder rate, rapid onset and long duration across a broad range of presbyopes ranging from 45 to 75 years of age and having a refractive range from -4.0 to +1.0D SE are consistent with features that patients are expecting from an effective treatment option. Based on these highly encouraging data, LENZ will direct towards NDA submission in mid-2024 for LNZ100, and preparations for commercialization in second half of 2025 upon FDA approval, with the goal of moving closer to helping many of the 128 million people experiencing symptoms of presbyopia in the United States.
Board Change • Mar 25No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. No independent directors (7 non-independent directors). Director Fred Guerard was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.